World's Best Scientists 2026 revealed!
Yannick Allanore

Yannick Allanore

D-Index & Metrics

Medicine

D-Index
106
Citations
52946
World Ranking
6410
National Ranking
186

Overview

Yannick Allanore is affiliated with Université Paris Cité in France. Their research primarily focuses on medicine, with a significant contribution in the fields of pathology and forensic medicine, pulmonary and respiratory medicine, rheumatology, epidemiology, and immunology.

The scientist's main topics of study encompass systemic sclerosis and related diseases, interstitial lung diseases and idiopathic pulmonary fibrosis, inflammatory myopathies and dermatomyositis, dermatologic treatments and research, rheumatoid arthritis research and therapies, mast cells and histamine, and autoimmune bullous skin diseases.

Yannick Allanore has contributed to publications in numerous venues. Frequent publication outlets include:

  • Annals of the Rheumatic Diseases
  • Revue du Rhumatisme
  • Lara D. Veeken
  • The Lancet Rheumatology
  • Journal of Scleroderma and Related Disorders

Their collaboration network features several frequently co-authored researchers such as:

  • Jérôme Avouac
  • Oliver Distler
  • Marco Matucci-Cerinic
  • Christopher P. Denton
  • Dinesh Khanna

Among the recent papers associated with or relevant to their research area are:

  • Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (2020), The Lancet Respiratory Medicine
  • Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database (2020), Annals of the Rheumatic Diseases
  • COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study (2021), The Lancet Rheumatology
  • Methotrexate and rheumatoid arthritis associated interstitial lung disease (2020), European Respiratory Journal
  • Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients (2020), Annals of the Rheumatic Diseases

Best Publications

  • 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative

    Frank Van Den Hoogen;Dinesh Khanna;Jaap Fransen;Sindhu R. Johnson

  • Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

    Anthony J. Tyndall;Bettina Bannert;Madelon Vonk;Paolo Airò

  • Update of EULAR recommendations for the treatment of systemic sclerosis

    Otylia Kowal-Bielecka;Jaap Fransen;Jerome Avouac;Mike Becker;Mike Becker

  • Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.

    Eric Hachulla;Virginie Gressin;Loïc Guillevin;Patrick Carpentier

  • Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

    Florence Tubach;Dominique Salmon;Philippe Ravaud;Yannick Allanore

  • Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

    Dinesh Khanna;Christopher P Denton;Angelika Jahreis;Jacob M van Laar

  • Mapping and predicting mortality from systemic sclerosis

    Muriel Elhai;Christophe Meune;Marouane Boubaya;Jérôme Avouac

  • Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies.

    Christophe Meune;Emmanuel Touzé;Ludovic Trinquart;Yannick Allanore

  • Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

    Dinesh Khanna;Celia J F Lin;Daniel E Furst;Jonathan Goldin

  • Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis

    Dinesh Khanna;Daniel E. Furst;Philip J. Clements;Yannick Allanore

  • Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group

    Jérôme Avouac;J. Fransen;U. A. Walker;V. Riccieri

  • Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases

    JE Gottenberg;L Guillevin;O Lambotte;B Combe

  • MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

    Pierre-Antoine Juge;Joyce S Lee;Esther Ebstein;Hiroshi Furukawa

  • Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

    Suzana Jordan;Jörg H W Distler;Britta Maurer;Dörte Huscher

  • Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies

    Muriel Elhai;Christophe Meune;Jérôme Avouac;André Kahan

  • Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database

    Florian M P Meier;Klaus W Frommer;Robert Dinser;Ulrich A Walker

  • Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies

    Jérôme Avouac;Paolo Airò;Christophe Meune;Lorenzo Beretta

  • High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.

    Y. Allanore;D. Borderie;J. Avouac;D. Zerkak

  • Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis

    Y. Allanore;C. Meune;M. C. Vonk;P. Airo

  • Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.

    Jacques-Eric Gottenberg;Florence Merle-Vincent;Fabrice Bentaberry;Yannick Allanore

Frequent Co-Authors

Marco Matucci-Cerinic
Marco Matucci-Cerinic University of Florence
Oliver Distler
Oliver Distler University of Zurich
Christopher P. Denton
Christopher P. Denton University College London
Paolo Airò
Paolo Airò University of Brescia
Eric Hachulla
Eric Hachulla University of Lille
Dinesh Khanna
Dinesh Khanna University of Michigan–Ann Arbor
Catherine Boileau
Catherine Boileau Université Paris Cité
Gabriela Riemekasten
Gabriela Riemekasten University of Lübeck
Luc Mouthon
Luc Mouthon Université Paris Cité
Ulf Müller-Ladner
Ulf Müller-Ladner University of Giessen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a medical career in the USA? There are many flexible, online options that can help you advance in the healthcare field without always requiring traditional, on-campus study.

For registered nurses, online rn-bsn programs without clinicals offer a seamless way to earn a bachelor’s degree while working, removing the need for additional clinical placements. If you’re looking to move into advanced practice or leadership, you might be interested in the shortest post master's dnp program options, which allow you to earn a Doctor of Nursing Practice in less time.

There are also dnp online programs available that offer accelerated coursework and flexible schedules, making them accessible for busy professionals. For those aiming to start their nursing journey as quickly as possible, a 9 month lpn program can fast-track entry into the healthcare workforce.

These online pathways make it easier than ever to upskill and find your place in the dynamic world of medicine—on your schedule and at your pace.

Best Scientists Citing Yannick Allanore

Trending Scientists

Recently Published Articles